RT Journal Article
SR Electronic
T1 Third dose of COVID-19 vaccine, CVnCoV, increased neutralizing activity against SARS-CoV-2 wild-type and Delta variant
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.22.22271051
DO 10.1101/2022.02.22.22271051
A1 Wolz, Olaf-Oliver
A1 Kays, Sarah-Katharina
A1 Junker, Helga
A1 Koch, Sven D.
A1 Mann, Philipp
A1 Quintini, Gianluca
A1 von Eisenhart-Rothe, Philipp
A1 Oostvogels, Lidia
YR 2022
UL http://medrxiv.org/content/early/2022/02/24/2022.02.22.22271051.abstract
AB A third dose of CVnCoV, a former candidate mRNA vaccine against SARS-CoV-2, was previously shown to boost neutralizing antibody responses against SARS-CoV-2 wild-type in adults aged 18-60 and >60 years in a phase 2a clinical study. Here we report neutralizing antibody responses to wild-type and a variant of concern, Delta, after a third dose on day (D) 57 and D180. Neutralization activity was assessed using a microneutralization assay. Comparable levels of neutralizing antibodies against wild-type and Delta were induced. These were higher than those observed after the first two doses, irrespective of age or pre-SARS-CoV-2-exposure status, indicating that the first two doses induced immune memory. Four weeks after the third dose on D180, neutralizing titers for wild-type and Delta were two-fold higher in younger participants than in older participants; seroconversion rates were 100% for wild-type and Delta in the younger group and for Delta in the older group. A third CVnCoV dose induced similar levels of neutralizing responses against wild-type virus and the Delta variant in both naïve and pre-exposed participants, aligning with current knowledge from licensed COVID-19 vaccines that a third dose is beneficial against SARS-CoV-2 variants.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04515147Funding StatementThis trial was funded by the German Federal Ministry of Education and Research (grant 01KI20703), and CureVac AGAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol was approved by the appropriate institutional and national ethics committees in Lima and Peru, and was registered at ClinicalTrials.gov NCT04515147. The trial was performed according to ICH E6 and Good Clinical Practice guidelines. All participants provided written informed consent at enrollment. The study was overseen by an internal Safety Review Committee (iSRC) and an independent Data Safety Monitoring Board (DSMB) composed of external expertsI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors